Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Janku

Showing results (181-190 of 277) with videos related to

Pageof 28
Sort By:
JCO Precision Oncology|July 14, 2022
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced CancersMohamed A Gouda, Helen J Huang, Sarina A Piha-Paul, et al.
Molecular Cancer Therapeutics|July 29, 2016
TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted TherapeuticsJennifer J Wheler, Filip Janku, Aung Naing, et al.
Oncoscience|January 15, 2015
Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experienceFernando F Corrales-Medina, Cynthia Herzog, Kenneth Hess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic CancerSeyed Pairawan, Kenneth R Hess, Filip Janku, et al.
The Oncologist|August 25, 2018
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast CancerReva K Basho, Clinton Yam, Michael Gilcrease, et al.
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b StudyKyaw Z Thein, Siqing Fu, Filip Janku, et al.
Blood|May 23, 2014
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester diseaseEli L Diamond, Lorenzo Dagna, David M Hyman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2017
Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care ActKenneth L Kehl, Cheryl P Fullmer, Siqing Fu, et al.
Scientific Reports|November 23, 2017
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitorsVikas Dembla, Roman Groisberg, Ken Hess, et al.
Cancer|October 29, 2020
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancersFilip Janku, Divya Sakamuri, Shumei Kato, et al.
Pageof 28

Showing results (181-190 of 277) with videos related to

Sort By:
Pageof 28
JCO Precision Oncology|July 14, 2022
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced CancersMohamed A Gouda, Helen J Huang, Sarina A Piha-Paul, et al.
Molecular Cancer Therapeutics|July 29, 2016
TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted TherapeuticsJennifer J Wheler, Filip Janku, Aung Naing, et al.
Oncoscience|January 15, 2015
Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experienceFernando F Corrales-Medina, Cynthia Herzog, Kenneth Hess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic CancerSeyed Pairawan, Kenneth R Hess, Filip Janku, et al.
The Oncologist|August 25, 2018
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast CancerReva K Basho, Clinton Yam, Michael Gilcrease, et al.
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b StudyKyaw Z Thein, Siqing Fu, Filip Janku, et al.
Blood|May 23, 2014
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester diseaseEli L Diamond, Lorenzo Dagna, David M Hyman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2017
Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care ActKenneth L Kehl, Cheryl P Fullmer, Siqing Fu, et al.
Scientific Reports|November 23, 2017
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitorsVikas Dembla, Roman Groisberg, Ken Hess, et al.
Cancer|October 29, 2020
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancersFilip Janku, Divya Sakamuri, Shumei Kato, et al.
Pageof 28